Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.

Gentilini LD, Jaworski FM, Tiraboschi C, Pérez IG, Kotler ML, Chauchereau A, Laderach DJ, Compagno D.

Oncotarget. 2017 Jul 4;8(27):44654-44668. doi: 10.18632/oncotarget.17963.

2.

In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.

Jaworski FM, Gentilini LD, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone N, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES.

Clin Cancer Res. 2017 Sep 1;23(17):5135-5148. doi: 10.1158/1078-0432.CCR-17-0112. Epub 2017 May 16.

PMID:
28512172
3.

Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells.

Bacigalupo ML, Manzi M, Espelt MV, Gentilini LD, Compagno D, Laderach DJ, Wolfenstein-Todel C, Rabinovich GA, Troncoso MF.

J Cell Physiol. 2015 Jun;230(6):1298-309. doi: 10.1002/jcp.24865.

PMID:
25469885
4.

Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.

Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G, Laderach DJ.

Glycobiology. 2014 Oct;24(10):899-906. doi: 10.1093/glycob/cwu055. Epub 2014 Jun 16.

PMID:
24939371
5.

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.

Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.

Supplemental Content

Loading ...
Support Center